The orthopedic market is attracting attention, and another new drug may be launched

【Pharmaceutical Network Industry News】Recently, Jiangsu Wanbang Biochemical Pharmaceutical submitted the marketing application of traditional Chinese medicine class 1.
1 new drug "Peony Medicine Relief Tablets" has been accepted by CDE, and the indication is degenerative joint disease
represented by knee osteoarthritis.
It is reported that Peony Medicine Relief Tablets is a new drug modified on the basis of the in-hospital preparation of Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine Blood Nourishing Soft Capsules, which is the experience of orthopedic expert Professor Shi Yinyu
.
The prescription is mainly composed of white peony, Qin Jiao, whole scorpion and other drugs, and has been used clinically in hospitals for many years
.
Clinical studies have shown that the improvement of clinical symptoms and signs of osteoarthritis is similar to that of commercial Chinese patent medicine anti-osteohyperplasia capsules and western drug glucosamine, and has anti-inflammatory and analgesic effects, and has a good effect on delaying cartilage degradation in early and middle knee osteoarthritis
.
It is understood that under the influence of factors such as the aging of the population, the improvement of national fitness awareness, and the expansion of sports injuries, the market demand for orthopedic drugs is continuing to expand
.
Among them, in 2021, the market sales of proprietary Chinese medicine patch plaster in China's urban physical pharmacies will be nearly 5 billion, a year-on-year increase of 5.
10%, while there are 15 varieties with sales of more than 100 million, and 7 products are orthopedic drugs, occupying most of the market share
of Chinese proprietary medicine patch plasters in urban physical pharmacies.
At present, in order to meet the growing market demand, in fact, many pharmaceutical companies and institutions are also focusing on the orthopedic track and are committed to bringing more drug options
to patients.
It is worth noting that at the same time, more and more new drugs have begun to emerge, in addition to Jiangsu Wanbang's peony medicine muscle relief tablets, this year there are a number of orthopedic new drugs have been approved for clinical and marketing
.
For example, in July, Kanghe Biotherapeutic Biological Products Class 1 new drug injection K11 was implicitly approved by the State Food and Drug Administration for clinical trials, and is intended to be used for the treatment
of degenerative cartilage wear lesions, osteoarthritis and other diseases.
K11 for injection is a recombinant human fibroblast growth factor, which aims to promote the proliferation of chondrocytes by activating FGF receptors, and realizing the effect of repairing the cartilage layer, so as to achieve the effect
of reversing the disease.
On April 21, Salubris teriparatide injection was approved for marketing by the NMPA
.
It is reported that the drug is a teriparatide injection water injection preparation, which is used for the treatment of osteoporosis in postmenopausal women with a high risk of fracture, once a day, without dissolving
before injection.
Teriparatide is the original product of Eli Lilly, which is a recombinant human parathyroid hormone (1-34) injection prepared by the expression of Escherichia coli, which was first approved for marketing in the United States in November 2002 and is the world's first osteogenesis-promoting drug
.
In China, the original product was approved for marketing
in March 2011.
The approved teriparatide injection (Xinfutai Pro) is an upgraded product of recombinant teriparatide (Xinfutai) for Salubris injection, which has been upgraded from a lyophilized powder needle to a liquid preparation
for automatic administration by an electronic injection pen.
In addition to the above drugs, according to data, as of February this year, 8 new drugs of skeletal musculoskeletal system Chinese class 1 have been submitted for marketing/clinical application, of which 2 have been approved for marketing and the remaining 6 have been approved for clinical
trials.
The industry believes that from the current situation of pharmaceutical companies continuously deploying the orthopedic drug market and the continuous emergence of new drugs, more Class 1 new drugs will come in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.